TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00718120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: One intramuscular injection into the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: One intramuscular injection into the deltoid region of the non-dominant arm
Study: NCT03731767

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Distraction thrust manipulation
Description: Distraction thrust manipulation of the talocural joint in supine position
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
Study: NCT01326455

Intervention type: DEVICE
Group type: OTHER
Intervention: Terumo TR wristband
Description: A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo TR wristband
Description: A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clo-Sur-P.A.D.
Description: A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1.
Study: NCT03072862

Intervention type: DEVICE
Intervention: Commercial Nucleus Cochlear Implant Systems
Description: Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
Study: NCT02762201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASI
Description: Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAC
Description: Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
Study: NCT01078779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
Study: NCT00411879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Epinephrine, and Steroids
Description: During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
Study: NCT05827185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ergonomic modifications
Description: A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ergonomic modifications and Physiotherapy
Description: A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Patient education
Description: Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
Study: NCT01836159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad Intervention
Description: Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
Study: NCT01836159

Intervention type: OTHER
Group type: OTHER
Intervention: Standard/ Usual Care
Description: Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
Study: NCT02959385

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study: NCT00411879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Epinephrine, Placebo
Description: Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
Study: NCT02959385

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiochemotherapy
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Radiochemotherapy
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study: NCT02454959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) with Aerochamber
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) without Aerochamber
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
Study: NCT03278977

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample for specific analyzes
Description: Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample for specific analyzes
Description: Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)
Study: NCT00145145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-3.A1 peptide and CpG 7909
Study: NCT03852069

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
Study: NCT02561195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection.
Study: NCT04838587

Intervention type: OTHER
Intervention: No intervention will be done
Description: No intervention,Only passive surveillance of Diarrhoea cases will be done
Study: NCT02734472

Intervention type: OTHER
Intervention: Incidence and risk factors of hypertension
Description: During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.

Intervention type: OTHER
Intervention: Incidence and risk factors of hypertension
Description: During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
Study: NCT02561195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection.
Study: NCT02079506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT00697255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
Study: NCT02561195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection
Study: NCT00697255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Follicle Stimulating Hormone (recFSH)
Description: Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human Chorion Gonadotropin (hCG)
Description: Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
Study: NCT01252927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASIST
Description: The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
Study: NCT02561195

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection
Study: NCT03293238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint line ultrasound
Description: Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Joint line landmark
Description: Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapatellar ultrasound guided
Description: Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Suprapatellar Landmark
Description: Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
Study: NCT00058526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic SB719125 (Primary)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic SB719125 (Primary)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic SB719125 (Primary)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic SB719125 (Primary)
Description: Intramuscular injection
Study: NCT01059253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AdvanStep training program - Turtle Pop
Description: Balance / mobility exercise program using the AdvanStep in a virtual reality context
Study: NCT02011620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-5-mononitrate
Description: Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
Study: NCT06524557

Intervention type: DIAGNOSTIC_TEST
Intervention: with chronic liver disease
Description: patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
Study: NCT00810485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration
Study: NCT02507869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affective response
Description: Participants adjust the intensity of their exercise to maintain a pleasant affective response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity heart rate
Description: Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
Study: NCT03709849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Description: the same as group description including dosage, frequency and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Description: the same as group description including dosage, frequency and duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
Description: the same as group description including dosage, frequency and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
Description: the same as group description including dosage, frequency and duration
Study: NCT05162339

Intervention type: OTHER
Intervention: No intervention was made
Description: No intervention was made
Study: NCT02873533

Intervention type: OTHER
Group type: OTHER
Intervention: geriatric care and longitudinal follow up
Description: geriatric care and longitudinal follow up
Study: NCT02280031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing placebo pill with lactose
Study: NCT01397006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
Study: NCT04236700

Intervention type: OTHER
Intervention: Oral clinical exam
Description: Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
Study: NCT02875782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation and DM specific component intervention
Description: A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: A simple, brief advice and a self-help general leaflet on smoking cessation
Study: NCT01137916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 800 mg